Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.
Shire's Angus Russell will retire from CEO post in 2013
After 13 years with Shire ($SHPG) and 32 years in the pharmaceutical business, CEO Angus Russell will retire next year. Flemming Ornskov will take over the top spot April 30, after a several-month handover period to ensure a smooth transition. Ornskov now serves as chief marketing officer and global head, strategic marketing for general and specialty medicine, at Bayer. "I've enjoyed every day of my time at Shire," Russell said. "I'm very pleased to have been a part of the growth story of this excellent company and to be leaving it in such great shape for further success." As CEO designate, Ornskov will spend time with all three Shire businesses, with a special focus initially on the specialty pharmaceuticals business. Release | Story
|
Biotech
> Verastem ($VSTM) appointed Joanna Horobin as chief medical officer. Release
> Celtaxsys appointed Brett Premack as chief technology officer. Release
> Valent BioSciences appointed Mike Daly as plant manager for its new biorational production facility in Osage, IA. Release
> Osiris Therapeutics ($OSIR) promoted Lode Debrabandere to chief operating officer. Release
> Incyte ($INCY) announced that Jim Daly will become executive vice president and chief commercial officer. Release
> Myos appointed Andrew J. Einhorn as its chief financial officer. Release
> Caprotec Bioanalytics named Jonathan Turner managing director and CEO. Release
> AP Pharma appointed Robert Rosen as senior vice president and chief commercial officer. Story
> Coherus BioSciences appointed George G. Montgomery as CFO. Release
> Solazyme ($SZYM) appointed Jean-Marc Rotsaert as COO. Release
> Accera appointed Joseph Jerkovich as director of marketing. Release
> Sutro Biopharma appointed Jeremy Bender as chief business officer and Aaron K. Sato as vice president of research. Release
Pharma Manufacturing
> Albany Molecular Research ($AMRI) announced that Steven R. Hagen has been promoted to senior vice president of pharmaceutical development and manufacturing. Release